Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06480227 · ClinicalTrials.gov registry record · NA

Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence

A NA study of Urinary Incontinence and Stress Urinary Incontinence, sponsored by NICHD Pelvic Floor Disorders Network.

Recruiting
Registry status
NA
Development phase
358
Enrollment target
7
Study locations

NCT06480227: Recruiting NA study of Urinary Incontinence and Stress Urinary Incontinence, sponsored by NICHD Pelvic Floor Disorders Network.

NCT06480227 is a NA study of Urinary Incontinence and Stress Urinary Incontinence that is actively recruiting participants, run by NICHD Pelvic Floor Disorders Network. The registered enrollment target is 358 participants, above the 255-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (40% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06480227, a NA study of Urinary Incontinence and Stress Urinary Incontinence, is actively recruiting participants, sponsored by NICHD Pelvic Floor Disorders Network.

RECRUITING
Registry status
NA
Development phase
358 participants
Enrollment target
7
Study locations

Study Summary

This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care. The Primary Aim is to determine the comparative effectiveness (as defined by "much" or "very much" better on PGI-I) of transurethral bulking agent (TBA) \[for 1 or 2 injections in 12 months\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).

Primary Outcome

The PGI-I is used to compare condition improvement, defined as (1) = very much better, (2) = much better, (3) = a little better, (4) = no change, (5) = a little worse, (6) much worse, (7) very much worse. Determine the comparative effectiveness (as defined by "much" or "very much" improved on PGI-I) of transurethral bulking agent \[for 1 or 2 injections in 12 months\] vs. single-incision sling 12 months after treatment intervention in women with predominant stress urinary incontinence.

Interventions

  • DEVICE Solyx Single-incision Sling
  • DEVICE Bulkamid Transurethral Bulking Agent

Study Locations (7)

California

  • University of California at San Diego - La Jolla
  • Kaiser Permanente -- San Diego - San Diego

Illinois

  • University of Chicago - Chicago

North Carolina

  • Duke University, Duke Division of Urogynecology and Reconstructive Pelvic Surgery - Durham

Pennsylvania

  • University of Pennsylvania - Philadelphia

Rhode Island

  • Brown/ Women and Infants Hospital of Rhode Island, Division of Urogynecology and Reconstructive Pelvic Surgery - Providence

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 358 participants
Start Date 2024-08-28
Est. Completion 2030-01-01
Phase NA

What NCT06480227 shows while recruiting

NCT06480227 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, above the 255-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (40% higher).

The record links to 3 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which Solyx Single-incision Sling is the first listed.

NCT06480227 lists 7 locations in 6 states (California, Illinois, North Carolina).

Frequently Asked Questions

What is clinical trial NCT06480227 about?

NCT06480227 is a clinical study titled "Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence". This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care. The Primary Aim is to determine the comparative effectiveness...

What is the current status of trial NCT06480227?

This trial is currently recruiting. It is a NA study. The enrollment target is 358 participants. The study started on 2024-08-28. Estimated completion is 2030-01-01.

What conditions does trial NCT06480227 study?

This clinical trial studies the following conditions: Urinary Incontinence, Stress Urinary Incontinence, Mixed Urinary Incontinence.

What interventions are being tested in trial NCT06480227?

The interventions under investigation include: Solyx Single-incision Sling (DEVICE), Bulkamid Transurethral Bulking Agent (DEVICE).

Who is sponsoring clinical trial NCT06480227?

This trial is sponsored by NICHD Pelvic Floor Disorders Network, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06480227 being conducted?

This trial has 7 study locations across California, Illinois, North Carolina, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06480227's enrollment target sits among peer trials

358 11th of 48 higher than 38 of 48 other Urinary Incontinence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04373317 · 358 participants · Phase 4

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

  • NCT05684965 · 358 participants · Phase 1

    XTX301 in Patients With Advanced Solid Tumors

  • NCT05824975 · 358 participants · Phase 1

    A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

  • NCT06859424 · 358 participants · Phase 2

    A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06480227, the US trial registry maintained by the National Library of Medicine. NCT06480227 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.